SAN FRANCISCO, Aug. 8, 2017 /PRNewswire/ -- Shareholder and
consumer rights law firm Schubert Jonckheer & Kolbe LLP has
launched an investigation into whether certain officers and
directors of Juno Therapeutics, Inc. ("Juno" or the "Company")
(NASDAQ: JUNO) breached their fiduciary duties to Juno and its
shareholders by exposing Juno to civil liability for failing to
disclose patient deaths in the Phase II/ROCKET trial of its leading
product candidate, JCAR015, during the period June 24, 2016 to November
22, 2016.
A motion to dismiss a class action lawsuit against Juno and its
CEO, CFO and Chief Medical Officer was recently denied by the U.S.
District Court for the Western District of Washington. The class action alleges that the
defendants recklessly failed to tell investors that patients were
dying from toxic side effects associated with JCAR015 during the
treatment's Phase II trial. The plaintiffs allege that the
defendants falsely represented that the deaths were attributable to
the use of fludarabine in combination with JCAR015 when they
actually knew that fludarabine had nothing to do with the deaths,
and instead were attributable to JCAR015 alone. Juno is
exposed to substantial potential liability through the class
action.
The Schubert Law Firm's investigation concerns when and how much
certain of Juno's officers and directors knew or should have known
about role of JCAR015 in the patient deaths that occurred during
the Phase II trial of JCAR015, and that the Company's
representations regarding the role of fludarabine were false or
misleading.
If you are a long-term holder of Juno stock and wish to obtain
additional information about the Schubert Law Firm's investigation
and your legal rights, please contact Miranda Kolbe via email at
mkolbe@schubertlawfirm.com or by telephone at (415) 788-4220, or
fill out the form on our website at
http://classactionlawyers.com/juno.
About Schubert Jonckheer & Kolbe
Schubert Jonckheer & Kolbe has extensive experience in
prosecuting securities claims, representing investors throughout
the nation in securities and shareholder lawsuits. Attorney
advertising. Prior results do not guarantee similar
outcomes.
View original
content:http://www.prnewswire.com/news-releases/executives-of-juno-therapeutics-under-investigation-300500927.html
SOURCE Schubert Jonckheer & Kolbe LLP